GLPG vs EXEL vs INCY vs ALKS vs JAZZ

For growth investors, Galapagos N.

V. (GLPG) is the stronger pick with 303. 5% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Galapagos N. V. (GLPG) offers the better valuation at 4. 9x trailing P/E, making it the more compelling value choice. Analysts rate Exelixis, Inc. (EXEL) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Galapagos N.

V. (GLPG) is the cheapest at 4. 9x versus Alkermes plc at 24. 8x. On forward P/E, Jazz Pharmaceuticals plc is actually cheaper at 9. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Exelixis, Inc.

(EXEL) delivered a total return of +84. 0%, compared to -63. 0% for Galapagos N. V. (GLPG). Over 10 years, the gap is even starker: EXEL returned +833. 5% versus GLPG's -41. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Jazz Pharmaceuticals plc (JAZZ) is the lower-risk stock at 0.

65β versus Alkermes plc's 1. 06β — meaning ALKS is approximately 64% more volatile than JAZZ relative to the S&P 500. On balance sheet safety, Galapagos N. V. (GLPG) carries a lower debt/equity ratio of 0% versus 126% for Jazz Pharmaceuticals plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Galapagos N.

V. (GLPG) is pulling ahead at 303. 5% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to -167. 5% for Jazz Pharmaceuticals plc. Over a 3-year CAGR, GLPG leads at 66. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Exelixis, Inc.

(EXEL) is the more profitable company, earning 33. 7% net margin versus -8. 3% for Jazz Pharmaceuticals plc — meaning it keeps 33. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GLPG leads at 45. 1% versus 5. 3% for JAZZ. At the gross margin level — before operating expenses — EXEL leads at 96. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Jazz Pharmaceuticals plc (JAZZ) trades at 9.

4x forward P/E versus 14. 0x for Exelixis, Inc. — 4. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALKS: 24. 3% to $44. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exelixis, Inc.

(EXEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 80), +833. 5% 10Y return). Both have compounded well over 10 years (EXEL: +833. 5%, ALKS: -11. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GLPG is a small-cap high-growth stock; EXEL is a mid-cap deep-value stock; INCY is a mid-cap high-growth stock; ALKS is a small-cap quality compounder stock; JAZZ is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.